Shanghai Shyndec Pharmaceutical Co Ltd (SHG:600420) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Shyndec Pharmaceutical Co Ltd (600420)
Shanghai Shyndec Pharmaceutical Co Ltd (SHG:600420) has a market capitalization of $1.89 Billion (CN¥12.92 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #6508 globally and #1486 in its home market, demonstrating a -1.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Shyndec Pharmaceutical Co Ltd's stock price CN¥9.63 by its total outstanding shares 1341172692 (1.34 Billion). Analyse Shanghai Shyndec Pharmaceutical Co Ltd operating cash flow efficiency to see how efficiently the company converts income to cash.
Shanghai Shyndec Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Shanghai Shyndec Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $3.39 Billion to $1.89 Billion (-4.52% CAGR).
Shanghai Shyndec Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Shyndec Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
Shanghai Shyndec Pharmaceutical Co Ltd's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.10x
Shanghai Shyndec Pharmaceutical Co Ltd's market cap is 2.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.03 Billion | $9.13 Billion | $476.93 Million | 0.33x | 6.34x |
| 2017 | $2.36 Billion | $8.52 Billion | $515.80 Million | 0.28x | 4.58x |
| 2018 | $1.70 Billion | $11.32 Billion | $705.52 Million | 0.15x | 2.42x |
| 2019 | $1.69 Billion | $12.20 Billion | $656.37 Million | 0.14x | 2.57x |
| 2020 | $1.81 Billion | $12.56 Billion | $648.79 Million | 0.14x | 2.79x |
| 2021 | $2.00 Billion | $13.94 Billion | $568.28 Million | 0.14x | 3.51x |
| 2022 | $1.77 Billion | $12.96 Billion | $627.79 Million | 0.14x | 2.82x |
| 2023 | $1.92 Billion | $12.07 Billion | $691.88 Million | 0.16x | 2.78x |
| 2024 | $2.34 Billion | $10.94 Billion | $1.08 Billion | 0.21x | 2.16x |
| 2025 | $1.98 Billion | $9.36 Billion | $944.38 Million | 0.21x | 2.10x |
Competitor Companies of 600420 by Market Capitalization
Companies near Shanghai Shyndec Pharmaceutical Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Shanghai Shyndec Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #501 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #530 globally with a market cap of $50.06 Billion USD ( CN¥342.11 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #541 globally with a market cap of $49.01 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #574 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #501 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.06 Billion | CN¥53.63 |
| #541 | Zoetis Inc | NYSE:ZTS | $49.01 Billion | $111.22 |
| #574 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $43.83 |
Shanghai Shyndec Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai Shyndec Pharmaceutical Co Ltd's market cap moved from $3.39 Billion to $ 1.89 Billion, with a yearly change of -4.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.89 Billion | -4.65% |
| 2025 | CN¥1.98 Billion | -15.41% |
| 2024 | CN¥2.34 Billion | +21.96% |
| 2023 | CN¥1.92 Billion | +8.55% |
| 2022 | CN¥1.77 Billion | -11.30% |
| 2021 | CN¥2.00 Billion | +10.15% |
| 2020 | CN¥1.81 Billion | +7.48% |
| 2019 | CN¥1.69 Billion | -1.09% |
| 2018 | CN¥1.70 Billion | -27.82% |
| 2017 | CN¥2.36 Billion | -21.98% |
| 2016 | CN¥3.03 Billion | -10.69% |
| 2015 | CN¥3.39 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Shanghai Shyndec Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.89 Billion USD |
| MoneyControl | $1.89 Billion USD |
| MarketWatch | $1.89 Billion USD |
| marketcap.company | $1.89 Billion USD |
| Reuters | $1.89 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate… Read more